Moderna Inc (NASDAQ:MRNA) Q1 2019 Earnings Conference Call - Final Transcript

May 18, 2020 • 08:30 am ET

Previous

Moderna Inc (NASDAQ:MRNA) Q1 2019 Earnings Conference Call - Final Transcript

Share
Close

Loading Event

Loading Transcript

Presentation
Operator
Operator

Good morning and welcome to the Moderna's Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that the call is being recorded. At this time, I'd like to turn the call over to Lavina Talukdar, Head of Investor Relations at Moderna.

Executive
Lavina Talukdar

Thank you, operator. Good morning everyone and welcome to Moderna's conference call to discuss the Interim Phase 1 Data for mRNA-1273, our vaccine against the novel coronavirus. You can access the press release issued this morning, as well as the slides that we'll be reviewing by going at Investors section of our website.

Speaking on today's call are Stephane Bancel, our Chief Executive Officer; Tal Zaks, our Chief Medical Officer; Stephen Hoge, our President; and Lorence Kim, our Chief Financial Officer.

Before we begin, please note that this conference call will include forward-looking statements. Please see Slide 2 of the accompanying presentation and our SEC [Technical Issues]. Before we begin, please note that this conference call will include forward-looking statements. [Technical Issues] for important risk factors, that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to update or revise the information provided on this call as a result of new information or future results or developments. With that, I will now turn the call over to Stephane.

Executive
Stephane Bancel

Thank you. Lavina. Good morning or good afternoon everyone and thank you for joining our call. One hour ago, we reported positive interim Phase 1 data for mRNA-1273, our development candidate against the novel coronavirus, as well as, mouse challenge data. We believe that these two datasets will present an important step forward towards the development of a vaccine candidate against SARS-CoV-2. We are encouraged by these interim data and it confirms our strategy to develop mRNA-1273 as fast as safely possible.

Let me briefly summarize the key takeaways from this morning's press release. We talked on new investment [Indecipherable] data. After two doses, a prime and a boost, all participants across the 25 microgram and the 100 microgram dose cohorts seroconverted with binding antibodies levels at or above levels seen in convalescent sera, which is the level of antibody in human blood after being infected by SARS-CoV-2 and recovered from SARS-CoV-2 disease. mRNA-1273 elicited neutralizing antibodies titer levels in all eight initial participants across the 25 microgram and the 100 microgram dose cohort, reaching or exceeding levels generally seen in convalescent sera. mRNA-1273 was generally well tolerated. We anticipated [Technical Issues].

We also announced between 25 [Phonetic] for pre-clinical mouse challenge study and with a successful vaccine candidate, we're entering one for several animal challenge models. This consists of vaccination of animals with the same dose regimens as that's used in clinical [Technical Issues], in this case a prime and a boost. These are placebo controlled studies. After vaccination, the animals are exposed to high levels of the